Vedanta brings home a win for lead microbiome program, passing a PhII test and clinching BARDA investment
Vedanta Biosciences wrapped up a Series D about two months ago to advance its microbiome research, but it’s not content to rest on its laurels.
The Cambridge, MA-based biotech claimed a win in a Phase II study treating Clostridioides difficile infection, saying its lead program achieved a statistically significant reduction in recurrences after eight weeks compared with placebo. It’s a result that ostensibly impressed the US government as the study results triggered a $23.8 million option from BARDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.